ClinicalTrials.gg
CompletedNCT01681472Updated Sep 25, 2020Results posted

PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer

A Phase 1/2 interventional study of 6R-MTHF (arfolitixorin) 200 mg/m2 and Levoleucovorin 200 mg/m2 in Colonic Neoplasms, sponsored by Isofol Medical AB. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-25.

Sponsored by Isofol Medical AB · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Colonic Neoplasms with a site in Sweden — 7 open to participants now, 12 under way, 2 of them phase 3. Colonic Neoplasms · Sweden.

Enrollment
21st of 24
32 · median 245
Started
2012
the only one that year
Phase 1/2
4 of 35
2 open now
Registered
13th of 35
by date
Lead sponsor
2 of 35
Isofol Medical AB

Among the 35 studies in Colonic Neoplasms with a site in Sweden, this one is the 21st largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2012, is one of 4 in phase 1/2, and was the 13th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

7 of the 35 studies in Colonic Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 328 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Colonic Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

The purpose of this study is to compare the concentration of four different metabolites in the tumor, in adjacent mucosa and in plasma in patients with colon cancer receiving two different doses of Modufolin (arfolitixorin) and Levoleucovorin (Isovorin®), respectively (60 and 200 mg/m2).

Read the detailed description

The purpose of this study is to compare the concentration of [6R] 5,10-methylene-THF, 5-formyl-THF, 5-methyl-THF and THF in the tumor, in adjacent mucosa and in plasma in patients with colon cancer receiving two different does of Modufolin® and Levoleucovorin (Isovorin®), respectively (60 and 200 mg/m2).

03

Conditions studied

  • Colonic Neoplasms

Keywords

  • Colon cancer
  • 5,10-methylenetetrahydrofolate
  • Rectal Neoplasms
  • Colorectal Neoplasms
  • Intestinal Neoplasms
  • Gastrointestinal Neoplasms
  • Digestive System Neoplasms
  • Gastrointestinal Diseases
  • Therapeutic Uses
  • Pharmacokinetics
  • Pharmacodynamics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Operable colon cancer amenable to curative surgery.
  • Performance status of 0 to 1
  • form
  • Patients must be at least 18 years of age.

Main Exclusion Criteria:

  • Any concurrent other anti-tumor therapy
  • Any prohibited concomitant medication within 30 days of surgery
  • Pregnancy or breast-feeding.
  • Second primary
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Levoleucovorin 200 mg/m2

    One i.v. bolus injection of study drug after the patient has been anaesthetized.

    Drug: Levoleucovorin 200 mg/m2

  • Active comparator
    Levoleucovorin 60 mg/m2

    One i.v. bolus injection of study drug after the patient has been anaesthetized.

    Drug: Levoleucovorin 60 mg/m2

  • Experimental
    6R-MTHF 200 mg/m2

    One i.v. bolus injection of study drug after the patient has been anaesthetized.

    Drug: 6R-MTHF (arfolitixorin) 200 mg/m2

  • Experimental
    6R-MTHF 60 mg/m2

    One i.v. bolus injection of study drug after the patient has been anaesthetized.

    Drug: 6R-MTHF (arfolitixorin) 60 mg/m2

Interventions

  • Drug6R-MTHF (arfolitixorin) 200 mg/m2

    Drug page: L-(+)-methylenetetrahydrofolic acid

    i.v. bolus injection

    Also known as: Modufolin®, ISO-901, [6R] 5,10-methylenetetrahydrofolate, arfolitixorin

  • DrugLevoleucovorin 200 mg/m2

    Drug page: Levoleucovorin

    i.v. bolus injection

    Also known as: Isovorin®

  • Drug6R-MTHF (arfolitixorin) 60 mg/m2

    Drug page: L-(+)-methylenetetrahydrofolic acid

    i.v. bolus injection

    Also known as: Modufolin®, ISO-901, [6R] 5,10-methylenetetrahydrofolate, arfolitixorin

  • DrugLevoleucovorin 60 mg/m2

    Drug page: Levoleucovorin

    i.v. bolus injection

    Also known as: Isovorin®

06

What researchers measure

Primary outcomes

  1. Concentration of [6R]-5,10-methylene-THF in Tumor Tissue

    Comparison of concentration of the active substance in Modufolin: \[6R\]-5,10-methylene-THF in tumor tissue after the different treatments.

    Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

  2. Concentration of [6R]-5,10-methylene-THF in Adjacent Mucosa Tissue

    Comparison of concentration of the active substance in Modufolin: \[6R\]-5,10-methylene-THF in mucosa adjacent to the tumor after the different treatments.

    Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

  3. Concentration of [6S]-5-THF in Tumor Tissue

    Comparison of concentration of the metabolite \[6S\]-5-THF in tumor after the different treatments.

    Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

  4. Concentration of [6S]-5-THF in Adjacent Mucosa Tissue

    Comparison of concentration of the metabolite \[6S\]-5-THF in mucosa adjacent to the tumor after the different treatments.

    Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

  5. Concentration of [6S]-5-methyl-THF in Tumor Tissue

    Comparison of concentration of the metabolite \[6S\]-5-methyl-THF in tumor after the different treatments.

    Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

  6. Concentration of [6S]-5-methyl-THF in Adjacent Mucosa Tissue

    Comparison of concentration of the metabolite \[6S\]-5-methyl-THF in mucosa adjacent to the tumor after the different treatments.

    Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

  7. Concentration of [6S]-5-formyl-THF in Tumor Tissue

    Comparison of concentration of the metabolite \[6S\]-5-formyl-THF in tumor after the different treatments.

    Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

  8. Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue

    Comparison of concentration of the metabolite \[6S\]-5-formyl-THF in mucosa adjacent to the tumor after the different treatments.

    Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration

Secondary outcomes

  1. AUC(0-2h) of [6R]-5,10-methylene-THF

    Area under the plasma concentration versus time curve from time 0 to 2 hours, for the active substance in Modufolin: \[6R\]-5,10-methylene-THF

    Time frame: Samples taken Day 1 (Day of surgery)

  2. AUC(0-2h) of [6S]-5-THF

    Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite \[6S\]-5-THF

    Time frame: Samples taken Day 1 (Day of surgery)

  3. AUC(0-2h) of [6S]-5-methyl-THF

    Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite: \[6S\]-5-methyl-THF

    Time frame: Samples taken Day 1 (Day of surgery)

  4. AUC(0-2h) of [6SR]-5-formyl-THF

    Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite \[6S\]-5-formyl-THF

    Time frame: Samples taken Day 1 (Day of surgery)

  5. AUC(Last) of [6R]-5,10-methylene-THF

    Area under the plasma concentration versus time curve, from time 0 to the last time point, for the active substance in Modufolin: \[6R\]-5,10-methylene-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  6. AUC(Last) of [6S]-5-THF

    Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite \[6S\]-5-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  7. AUC(Last) of [6S]-5-methyl-THF

    Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite \[6S\]-5-methyl-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  8. AUC(Last) of [6S]-5-formyl-THF

    Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite \[6S\]-5-formyl-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  9. Cmax of [6R]-5,10-methylene-THF

    Maximum concentration (Cmax) in plasma of the active substance in Modufolin: \[6R\]-5,10-methylene-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  10. Cmax of [6S]-5-THF in Plasma

    Maximum concentration (Cmax) in plasma of the metabolite \[6S\]-5-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  11. Cmax of [6S]-5-methyl-THF in Plasma

    Maximum concentration (Cmax) in plasma of the metabolite \[6S\]-5-methyl-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  12. Cmax of [6S]-5-formyl-THF in Plasma

    Maximum concentration (Cmax) in plasma of the active substance in Modufolin: \[6R\] 5,10- methylene-THF and the metabolites: \[6S\]-5-THF, \[6S\]-5-methyl-THF, and \[6S\]-5-formyl-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  13. Tmax of [6R]-5,10-methylene-THF

    Timepoint (tmax) when Cmax in plasma occurs of the active substance in Modufolin: \[6R\]-5,10-methylene-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  14. Tmax of [6S]-5-THF

    Timepoint (tmax) when Cmax in plasma occurs for the metabolite \[6S\]-5-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  15. Tmax of [6S]-5-methyl-THF

    Timepoint (tmax) when Cmax in plasma occurs for the metabolite \[6S\]-5-methyl-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  16. Tmax of [6S]-5-formyl-THF

    Timepoint (tmax) when Cmax in plasma occurs for the metabolite \[6S\]-5-formyl-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  17. T(1/2) of [6R]-5,10-methylene-THF

    Terminal plasma elimination half-life time for the active substance in Modufolin: \[6R\]-5,10-methylene-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  18. T(1/2) of [6S]-5-THF

    Terminal plasma elimination half-life time for the metabolite \[6S\]-5-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  19. T(1/2) of [6S]-5-methyl-THF

    Terminal plasma elimination half-life time for the metabolite \[6S\]-5-methyl-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  20. T(1/2) of [6S]-5-formyl-THF

    Terminal plasma elimination half-life time for the metabolite \[6S\]-5-formyl-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  21. T(Last) of [6R]-5,10-methylene-THF

    The time-point for the last measurable concentration of the active substance in Modufolin: \[6R\]-5,10-methylene-THF

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  22. T(Last) of [6S]-5-THF

    The time-point for the last measurable concentration for the metabolite \[6S\]-5-TH in plasma

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  23. T(Last) of [6S]-5-methyl-THF

    The time-point for the last measurable concentration for the metabolite \[6S\]-5-methyl-THF in plasma

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  24. T(Last) of [6S]-5-formyl-THF

    The time-point for the last measurable concentration for the metabolite \[6S\]-5-formyl-THF in plasma

    Time frame: Samples taken Day 1 (Day of surgery) and Day 2

  25. Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6R]-5,10-methylene-THF

    Correlation between the exposure of \[6R\]-5,10-methylene-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6R\]-5,10-methylene-THF in the tumor or adjacent mucosa at surgery.

    Time frame: Samples taken Day 1 (Day of surgery)

  26. Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-THF

    Correlation between the exposure of \[6S\]-5-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6S\]-5-THF in the tumor or adjacent mucosa at surgery.

    Time frame: Samples taken Day 1 (Day of surgery)

  27. Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-methyl-THF

    Correlation between the exposure of \[6S\]-5-methyl-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6S\]-5-methyl-THF in the tumor or adjacent mucosa at surgery.

    Time frame: Samples taken Day 1 (Day of surgery)

  28. Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-formyl-THF

    Correlation between the exposure of \[6S\]-5-formyl-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6S\]-5-formyl-THF in the tumor or adjacent mucosa at surgery.

    Time frame: Samples taken Day 1 (Day of surgery)

  29. Gene Expression Ratios (Mucosa:Tumor)

    Concentration of different genes involved in folate transport and metabolism were analysed in both tumor and adjacent mucosa. The concentration in mucosa was divided by the concentration in tumor. A value above 1 indicate that the gene expression was higher in mucosa than in tumor and a value below 1 that the gene expression was higher in tumor than in mucosa.

    Time frame: Sample taken Day 1 (Day of Surgery)

  30. Correlation of Gene Expression in Tumor and Adjacent Mucosa

    Concentration of the gene expression was analysed in both tumor and adjacent mucosa. The presence of any correlation between the results (i.e., concentration of the gene expression in tumor versus adjacent mucosa) was evaluated for each treatment. No evaluation was done between treatments.

    Time frame: Sample taken Day 1 (Day of Surgery)

  31. Homocystein Concentration

    Blood samples for folate biomarker (homocystein) analysis were collected at Screening, Day 2, and Day 5 (End of study visit).

    Time frame: Samples taken at Screening visit, Day 2, and End of Study (Day 5)

  32. S-Folate Concentration

    Blood samples for folate biomarker (S-folate) analysis were collected at Screening, Day 2 and Day 5 (End of study visit).

    Time frame: Samples taken at Screening visit, Day 2 and End of Study (Day 5)

  33. Change in Homocystein Concentration From Screening

    Blood samples for folate biomarker (homocystein) analysis were collected at Screening, Day 2 and Day 5 (End of study visit). Changes from screening to later visits were counted. The criteria for assessment categories "normal", "low" and "high" were based on the reference ranges for plasma-Homocystein as follows: "low" \<4,7 mcmol/L; "normal" =\> 4,7 and \<=16 mcmol/L; "high" \>16 mcmol/L. Values were applicable for both male and female adults.

    Time frame: Samples taken at Screening visit, Day 2 and End of Study (Day 5)

  34. Change in S-Folate Concentration From Screening

    Blood samples for folate biomarker (S-folate) analysis were collected at Screening, Day 2 and Day 5 (End of study visit). Changes from screening to later visits were counted.

    Time frame: Samples taken at Screening visit, Day 2 and End of Study (Day 5)

  35. Number of AEs Per Severity

    Number of reported AEs per treatment with respect to severity

    Time frame: Screening visit until end of study, Day 5

07

Results

Posted Jul 17, 2015

Participant flow

Participant flow — Overall Study
MilestoneLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m26R-MTHF 200 mg/m26R-MTHF 60 mg/m2
Started8888
Completed8788
Not completed0100
Withdrew: Adverse event0100

Outcome measures

PrimaryConcentration of [6R]-5,10-methylene-THF in Tumor Tissue

Comparison of concentration of the active substance in Modufolin: \[6R\]-5,10-methylene-THF in tumor tissue after the different treatments.

Time frame:
Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Reported as:
Mean · pmol/g
Concentration of [6R]-5,10-methylene-THF in Tumor Tissue
pmol/gLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
Concentration of [6R]-5,10-methylene-THF in Tumor Tissue1871 ± 1159959 ± 4174725 ± 22102393 ± 1920
Statistical analysis
  • Modufolin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0323
  • Levoleucovorin 60 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.1336
  • Levoleucovorin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.8622
  • Levoleucovorin 60 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0024
  • Levoleucovorin 200 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0074
  • Levoleucovorin 200 mg/m2 vs Levoleucovorin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.1752
PrimaryConcentration of [6R]-5,10-methylene-THF in Adjacent Mucosa Tissue

Comparison of concentration of the active substance in Modufolin: \[6R\]-5,10-methylene-THF in mucosa adjacent to the tumor after the different treatments.

Time frame:
Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Reported as:
Mean · pmol/g
Concentration of [6R]-5,10-methylene-THF in Adjacent Mucosa Tissue
pmol/gLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
Concentration of [6R]-5,10-methylene-THF in Adjacent Mucosa Tissue1333 ± 852626 ± 4395099 ± 39273481 ± 3926
Statistical analysis
  • Modufolin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.1480
  • Levoleucovorin 60 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0034
  • Levoleucovorin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0177
  • Levoleucovorin 60 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = <0.0001
  • Levoleucovorin 200 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0019
  • Levoleucovorin 200 mg/m2 vs Levoleucovorin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0118
PrimaryConcentration of [6S]-5-THF in Tumor Tissue

Comparison of concentration of the metabolite \[6S\]-5-THF in tumor after the different treatments.

Time frame:
Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Reported as:
Mean · pmol/g
Concentration of [6S]-5-THF in Tumor Tissue
pmol/gLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
Concentration of [6S]-5-THF in Tumor Tissue1329 ± 720933 ± 5984175 ± 31272219 ± 1995
Statistical analysis
  • Modufolin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.1182
  • Levoleucovorin 60 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0538
  • Levoleucovorin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.5244
  • Levoleucovorin 60 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0081
  • Levoleucovorin 200 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0313
  • Levoleucovorin 200 mg/m2 vs Levoleucovorin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.4777
PrimaryConcentration of [6S]-5-THF in Adjacent Mucosa Tissue

Comparison of concentration of the metabolite \[6S\]-5-THF in mucosa adjacent to the tumor after the different treatments.

Time frame:
Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Reported as:
Mean · pmol/g
Concentration of [6S]-5-THF in Adjacent Mucosa Tissue
pmol/gLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
Concentration of [6S]-5-THF in Adjacent Mucosa Tissue1333 ± 852626 ± 4395099 ± 39273481 ± 3926
Statistical analysis
  • Modufolin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.2716
  • Levoleucovorin 60 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0124
  • Levoleucovorin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0728
  • Levoleucovorin 60 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = <0.0001
  • Levoleucovorin 200 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0039
  • Levoleucovorin 200 mg/m2 vs Levoleucovorin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0454
PrimaryConcentration of [6S]-5-methyl-THF in Tumor Tissue

Comparison of concentration of the metabolite \[6S\]-5-methyl-THF in tumor after the different treatments.

Time frame:
Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Reported as:
Mean · pmol/g
Concentration of [6S]-5-methyl-THF in Tumor Tissue
pmol/gLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
Concentration of [6S]-5-methyl-THF in Tumor Tissue3574 ± 24151904 ± 9184396 ± 18581882 ± 1204
Statistical analysis
  • Modufolin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0092
  • Levoleucovorin 60 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.8303
  • Levoleucovorin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.1182
  • Levoleucovorin 60 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0081
  • Levoleucovorin 200 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.3184
  • Levoleucovorin 200 mg/m2 vs Levoleucovorin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.1752
PrimaryConcentration of [6S]-5-methyl-THF in Adjacent Mucosa Tissue

Comparison of concentration of the metabolite \[6S\]-5-methyl-THF in mucosa adjacent to the tumor after the different treatments.

Time frame:
Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Reported as:
Mean · pmol/g
Concentration of [6S]-5-methyl-THF in Adjacent Mucosa Tissue
pmol/gLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
Concentration of [6S]-5-methyl-THF in Adjacent Mucosa Tissue3667 ± 20431216 ± 4552494 ± 7652066 ± 1517
Statistical analysis
  • Modufolin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0728
  • Levoleucovorin 60 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.2246
  • Levoleucovorin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0428
  • Levoleucovorin 60 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0003
  • Levoleucovorin 200 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.4309
  • Levoleucovorin 200 mg/m2 vs Levoleucovorin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0055
PrimaryConcentration of [6S]-5-formyl-THF in Tumor Tissue

Comparison of concentration of the metabolite \[6S\]-5-formyl-THF in tumor after the different treatments.

Time frame:
Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Reported as:
Mean · pmol/g
Concentration of [6S]-5-formyl-THF in Tumor Tissue
pmol/gLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
Concentration of [6S]-5-formyl-THF in Tumor Tissue3611 ± 3899512 ± 259100 ± 4757 ± 48
Statistical analysis
  • Modufolin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0728
  • Levoleucovorin 60 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0034
  • Levoleucovorin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0015
  • Levoleucovorin 60 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0024
  • Levoleucovorin 200 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0009
  • Levoleucovorin 200 mg/m2 vs Levoleucovorin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0055
PrimaryConcentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue

Comparison of concentration of the metabolite \[6S\]-5-formyl-THF in mucosa adjacent to the tumor after the different treatments.

Time frame:
Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Reported as:
Mean · pmol/g
Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue
pmol/gLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue5456 ± 39631403 ± 64082 ± 7742 ± 18
Statistical analysis
  • Modufolin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0240
  • Levoleucovorin 60 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0058
  • Levoleucovorin 200 mg/m2 vs Modufolin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0015
  • Levoleucovorin 60 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = <0.0001
  • Levoleucovorin 200 mg/m2 vs Modufolin 200 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0014
  • Levoleucovorin 200 mg/m2 vs Levoleucovorin 60 mg/m2 · Wilcoxon (Mann-Whitney) · p = 0.0338
SecondaryAUC(0-2h) of [6R]-5,10-methylene-THF

Area under the plasma concentration versus time curve from time 0 to 2 hours, for the active substance in Modufolin: \[6R\]-5,10-methylene-THF

Time frame:
Samples taken Day 1 (Day of surgery)
Reported as:
Mean · mcg*h/L
AUC(0-2h) of [6R]-5,10-methylene-THF
mcg*h/LL-LV(200)L-LV(60)Mod(200)Mod(60)
AUC(0-2h) of [6R]-5,10-methylene-THF326.40261 ± 61.98416239.90076 ± 07734.09113 ± 1557.765520 ± 0
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryAUC(0-2h) of [6S]-5-THF

Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite \[6S\]-5-THF

Time frame:
Samples taken Day 1 (Day of surgery)
Reported as:
Mean · mcg*h/L
AUC(0-2h) of [6S]-5-THF
mcg*h/LL-LV(200)L-LV(60)Mod(200)Mod(60)
AUC(0-2h) of [6S]-5-THF827.1083 ± 178.23243640.0489 ± 019408.1712 ± 3000.647945639.2700 ± 885.82223
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0009
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryAUC(0-2h) of [6S]-5-methyl-THF

Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite: \[6S\]-5-methyl-THF

Time frame:
Samples taken Day 1 (Day of surgery)
Reported as:
Mean · mcg*h/L
AUC(0-2h) of [6S]-5-methyl-THF
mcg*h/LL-LV(200)L-LV(60)Mod(200)Mod(60)
AUC(0-2h) of [6S]-5-methyl-THF2336.24432 ± 829.186341258.60184 ± 247.513532277.89290 ± 1132.95603997.74091 ± 413.68052
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0728
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.2246
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0166
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.1752
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.9581
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0.0118
SecondaryAUC(0-2h) of [6SR]-5-formyl-THF

Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite \[6S\]-5-formyl-THF

Time frame:
Samples taken Day 1 (Day of surgery)
Reported as:
Mean · mcg*h/L
AUC(0-2h) of [6SR]-5-formyl-THF
mcg*h/LL-LV(200)L-LV(60)Mod(200)Mod(60)
AUC(0-2h) of [6SR]-5-formyl-THF29911.9184 ± 6924.780317595.4599 ± 764.276500 ± 00 ± 0
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0.0024
SecondaryAUC(Last) of [6R]-5,10-methylene-THF

Area under the plasma concentration versus time curve, from time 0 to the last time point, for the active substance in Modufolin: \[6R\]-5,10-methylene-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · mcg*h/L
AUC(Last) of [6R]-5,10-methylene-THF
mcg*h/LL-LV(200)L-LV(60)Mod(200)Mod(60)
AUC(Last) of [6R]-5,10-methylene-THF462.10746 ± 221.85761239.90076 ± 07910.61038 ± 1623.243002272.78010 ± 448.01407
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0022
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryAUC(Last) of [6S]-5-THF

Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite \[6S\]-5-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · mcg*h/L
AUC(Last) of [6S]-5-THF
mcg*h/LL-LV(200)L-LV(60)Mod(200)Mod(60)
AUC(Last) of [6S]-5-THF2231.1443 ± 1051.06650640.0489 ± 028466.5389 ± 5303.287056766.9104 ± 1484.91243
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0009
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryAUC(Last) of [6S]-5-methyl-THF

Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite \[6S\]-5-methyl-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · mcg*h/L
AUC(Last) of [6S]-5-methyl-THF
mcg*h/LL-LV(200)L-LV(60)Mod(200)Mod(60)
AUC(Last) of [6S]-5-methyl-THF32206.2771 ± 9121.18187689.0921 ± 5164.609821737.2428 ± 21757.15455495.1924 ± 6110.0065
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0240
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.1336
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.2725
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.1893
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0.0024
SecondaryAUC(Last) of [6S]-5-formyl-THF

Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite \[6S\]-5-formyl-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · mcg*h/L
AUC(Last) of [6S]-5-formyl-THF
mcg*h/LL-LV(200)L-LV(60)Mod(200)Mod(60)
AUC(Last) of [6S]-5-formyl-THF43429.1885 ± 12411.28449637.0308 ± 1637.211875.6174 ± 69.217650.1858 ± 0
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0142
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0085
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0.0024
SecondaryCmax of [6R]-5,10-methylene-THF

Maximum concentration (Cmax) in plasma of the active substance in Modufolin: \[6R\]-5,10-methylene-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · µg/L
Cmax of [6R]-5,10-methylene-THF
µg/LL-LV(200)L-LV(60)Mod(200)Mod(60)
Cmax of [6R]-5,10-methylene-THF195.0000 ± 40.76763123.0000 ± 022087.5000 ± 5635.458536452.8571 ± 559.18477
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0014
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0021
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0014
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryCmax of [6S]-5-THF in Plasma

Maximum concentration (Cmax) in plasma of the metabolite \[6S\]-5-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · µg/L
Cmax of [6S]-5-THF in Plasma
µg/LL-LV(200)L-LV(60)Mod(200)Mod(60)
Cmax of [6S]-5-THF in Plasma577.6250 ± 190.74436335.0000 ± 013372.5000 ± 2108.159325015.7143 ± 427.35064
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0009
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryCmax of [6S]-5-methyl-THF in Plasma

Maximum concentration (Cmax) in plasma of the metabolite \[6S\]-5-methyl-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · µg/L
Cmax of [6S]-5-methyl-THF in Plasma
µg/LL-LV(200)L-LV(60)Mod(200)Mod(60)
Cmax of [6S]-5-methyl-THF in Plasma2786.25000 ± 822.62531078.00000 ± 275.262062020.50000 ± 1142.25116800.42857 ± 396.41849
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0240
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.1336
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.1551
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.1563
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0.0024
SecondaryCmax of [6S]-5-formyl-THF in Plasma

Maximum concentration (Cmax) in plasma of the active substance in Modufolin: \[6R\] 5,10- methylene-THF and the metabolites: \[6S\]-5-THF, \[6S\]-5-methyl-THF, and \[6S\]-5-formyl-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · µg/L
Cmax of [6S]-5-formyl-THF in Plasma
µg/LL-LV(200)L-LV(60)Mod(200)Mod(60)
Cmax of [6S]-5-formyl-THF in Plasma32962.5000 ± 8594.1736910168.3333 ± 2271.47896252.7500 ± 141.51178261.0000 ± 0
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0142
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0085
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0.0024
SecondaryTmax of [6R]-5,10-methylene-THF

Timepoint (tmax) when Cmax in plasma occurs of the active substance in Modufolin: \[6R\]-5,10-methylene-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · h
Tmax of [6R]-5,10-methylene-THF
hL-LV(200)L-LV(60)Mod(200)Mod(60)
Tmax of [6R]-5,10-methylene-THF1.14285857 ± 0.530796051.00000000 ± 00.08333000 ± 0.000000000.08333000 ± 0.00000000
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 1.0000
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0010
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0005
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryTmax of [6S]-5-THF

Timepoint (tmax) when Cmax in plasma occurs for the metabolite \[6S\]-5-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · h
Tmax of [6S]-5-THF
hL-LV(200)L-LV(60)Mod(200)Mod(60)
Tmax of [6S]-5-THF2.02083375 ± 1.036773601.50000000 ± 00.38541750 ± 0.247759360.09523571 ± 0.03149956
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0056
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0010
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0014
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryTmax of [6S]-5-methyl-THF

Timepoint (tmax) when Cmax in plasma occurs for the metabolite \[6S\]-5-methyl-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · h
Tmax of [6S]-5-methyl-THF
hL-LV(200)L-LV(60)Mod(200)Mod(60)
Tmax of [6S]-5-methyl-THF4.75000000 ± 1.388730152.41666667 ± 0.664580073.75000000 ± 1.164964752.92857143 ± 0.93222724
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.1796
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.3243
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0263
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0268
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.2041
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0.0061
SecondaryTmax of [6S]-5-formyl-THF

Timepoint (tmax) when Cmax in plasma occurs for the metabolite \[6S\]-5-formyl-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · h
Tmax of [6S]-5-formyl-THF
hL-LV(200)L-LV(60)Mod(200)Mod(60)
Tmax of [6S]-5-formyl-THF0.12499750 ± 0.089087530.08333000 ± 0.000000000.10416500 ± 0.041670000.08333000 ± 0
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryT(1/2) of [6R]-5,10-methylene-THF

Terminal plasma elimination half-life time for the active substance in Modufolin: \[6R\]-5,10-methylene-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · h
T(1/2) of [6R]-5,10-methylene-THF
hL-LV(200)L-LV(60)Mod(200)Mod(60)
T(1/2) of [6R]-5,10-methylene-THF3.07069184 ± 2.489581599.12204918 ± 00.90893994 ± 0.625864200.34368840 ± 0.06725217
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0268
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0227
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0933
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryT(1/2) of [6S]-5-THF

Terminal plasma elimination half-life time for the metabolite \[6S\]-5-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · h
T(1/2) of [6S]-5-THF
hL-LV(200)L-LV(60)Mod(200)Mod(60)
T(1/2) of [6S]-5-THF5.59459251 ± 1.769820920 ± 01.24808943 ± 0.239959730.96378070 ± 0.19174152
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0177
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0058
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0043
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryT(1/2) of [6S]-5-methyl-THF

Terminal plasma elimination half-life time for the metabolite \[6S\]-5-methyl-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · h
T(1/2) of [6S]-5-methyl-THF
hL-LV(200)L-LV(60)Mod(200)Mod(60)
T(1/2) of [6S]-5-methyl-THF7.0955575 ± 1.1898159710.7281060 ± 8.808120649.0743346 ± 3.843172268.5121573 ± 2.80644764
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryT(1/2) of [6S]-5-formyl-THF

Terminal plasma elimination half-life time for the metabolite \[6S\]-5-formyl-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · h
T(1/2) of [6S]-5-formyl-THF
hL-LV(200)L-LV(60)Mod(200)Mod(60)
T(1/2) of [6S]-5-formyl-THF1.51328500 ± 0.341081310.98944069 ± 0.202173670.23180085 ± 0.134389010 ± 0
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0668
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0502
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0.0081
SecondaryT(Last) of [6R]-5,10-methylene-THF

The time-point for the last measurable concentration of the active substance in Modufolin: \[6R\]-5,10-methylene-THF

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · h
T(Last) of [6R]-5,10-methylene-THF
hL-LV(200)L-LV(60)Mod(200)Mod(60)
T(Last) of [6R]-5,10-methylene-THF3.00000000 ± 1.414213562.00000000 ± 03.25000000 ± 1.388730151.35714286 ± 0.24397502
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0011
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.6691
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryT(Last) of [6S]-5-THF

The time-point for the last measurable concentration for the metabolite \[6S\]-5-TH in plasma

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · h
T(Last) of [6S]-5-THF
hL-LV(200)L-LV(60)Mod(200)Mod(60)
T(Last) of [6S]-5-THF4.75000000 ± 1.488047622.00000000 ± 05.75000000 ± 0.707106783.42857143 ± 0.78679579
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0015
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0640
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.1213
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0
SecondaryT(Last) of [6S]-5-methyl-THF

The time-point for the last measurable concentration for the metabolite \[6S\]-5-methyl-THF in plasma

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · h
T(Last) of [6S]-5-methyl-THF
hL-LV(200)L-LV(60)Mod(200)Mod(60)
T(Last) of [6S]-5-methyl-THF24.0000000 ± 0.0000000012.0000000 ± 9.2951600315.0000000 ± 9.621404718.5714286 ± 6.80336051
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.1791
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.4945
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0.0014
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.5990
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0303
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0.0107
SecondaryT(Last) of [6S]-5-formyl-THF

The time-point for the last measurable concentration for the metabolite \[6S\]-5-formyl-THF in plasma

Time frame:
Samples taken Day 1 (Day of surgery) and Day 2
Reported as:
Mean · h
T(Last) of [6S]-5-formyl-THF
hL-LV(200)L-LV(60)Mod(200)Mod(60)
T(Last) of [6S]-5-formyl-THF6.00000000 ± 0.000000008.33333333 ± 7.737355280.33333500 ± 0.235702260.16667000 ± 0
Statistical analysis
  • Mod(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(200) vs Mod(60) · Wilcoxon (Mann-Whitney) · p = 0
  • L-LV(60) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0125
  • L-LV(200) vs Mod(200) · Wilcoxon (Mann-Whitney) · p = 0.0017
  • L-LV(200) vs L-LV(60) · Wilcoxon (Mann-Whitney) · p = 0.5286
SecondaryCorrelation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6R]-5,10-methylene-THF

Correlation between the exposure of \[6R\]-5,10-methylene-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6R\]-5,10-methylene-THF in the tumor or adjacent mucosa at surgery.

Time frame:
Samples taken Day 1 (Day of surgery)
Reported as:
Number · correlation coefficient
Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6R]-5,10-methylene-THF
correlation coefficientLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
AUC(0-2h) vs. conc in tumor0.54039NA-0.21666—
AUC(0-2h) vs. conc in adjacent mucosa0.68223NA0.27618—
Statistical analysis
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.6063 · Correlation factor: -0.21666
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.2105 · Correlation factor: 0.54039
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.5079 · Correlation factor: 0.27618
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.0913 · Correlation factor: 0.68223
SecondaryCorrelation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-THF

Correlation between the exposure of \[6S\]-5-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6S\]-5-THF in the tumor or adjacent mucosa at surgery.

Time frame:
Samples taken Day 1 (Day of surgery)
Reported as:
Number · correlation coefficient
Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-THF
correlation coefficientLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
AUC(0-2h) vs. conc in tumor-0.02188NA0.270180.38298
AUC(0-2h) vs. conc in adjacent mucosa0.07937NA0.349050.45404
Statistical analysis
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.3964 · Correlation factor: 0.38298
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.5175 · Correlation factor: 0.27018
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.9590 · Correlation factor: -0.02188
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.3061 · Correlation factor: 0.45404
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.3967 · Correlation factor: 0.34905
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.8518 · Correlation factor: 0.07937
SecondaryCorrelation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-methyl-THF

Correlation between the exposure of \[6S\]-5-methyl-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6S\]-5-methyl-THF in the tumor or adjacent mucosa at surgery.

Time frame:
Samples taken Day 1 (Day of surgery)
Reported as:
Number · correlation coefficient
Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-methyl-THF
correlation coefficientLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
AUC(0-2h) vs. conc in tumor0.737430.447570.032920.09033
AUC(0-2h) vs. conc in adjacent mucosa0.765020.34496-0.662950.36854
Statistical analysis
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.0586 · Correlation factor: 0.73743
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.2661 · Correlation factor: 0.44757
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.9506 · Correlation factor: 0.03292
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.8315 · Correlation factor: 0.09033
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.0451 · Correlation factor: 0.76502
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.4027 · Correlation factor: 0.34496
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.1513 · Correlation factor: -0.66295
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.3690 · Correlation factor: 0.36854
SecondaryCorrelation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-formyl-THF

Correlation between the exposure of \[6S\]-5-formyl-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6S\]-5-formyl-THF in the tumor or adjacent mucosa at surgery.

Time frame:
Samples taken Day 1 (Day of surgery)
Reported as:
Number · correlation coefficient
Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-formyl-THF
correlation coefficientLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
AUC(0-2h) vs. conc in tumor0.687780.11512——
AUC(0-2h) vs. conc in adjacent mucosa0.235120.02576——
Statistical analysis
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.5751 · Correlation factor: 0.23512
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.9672 · Correlation factor: 0.02576
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.0594 · Correlation factor: 0.68778
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.8281 · Correlation factor: 0.11512
SecondaryGene Expression Ratios (Mucosa:Tumor)

Concentration of different genes involved in folate transport and metabolism were analysed in both tumor and adjacent mucosa. The concentration in mucosa was divided by the concentration in tumor. A value above 1 indicate that the gene expression was higher in mucosa than in tumor and a value below 1 that the gene expression was higher in tumor than in mucosa.

Time frame:
Sample taken Day 1 (Day of Surgery)
Reported as:
Number · Ratio
Gene Expression Ratios (Mucosa:Tumor)
RatioModufolin 60 mg/m2Modufolin 200 mg/m2Levoleucovorin 60 mg/m2Levoleucovorin 200 mg/m2
AMT1.355.601.863.33
PCFT2.032.752.922.45
FPGS0.470.700.630.83
MTHFS0.510.870.830.72
ABCC31.833.372.484.15
GGH0.500.470.350.31
ABCC10.410.550.770.43
MTHFD1L0.150.240.290.35
SHMT10.891.130.722.26
SHMT20.310.340.380.48
RFC-10.480.660.531.18
Statistical analysis
  • Modufolin 60 mg/m2 · pearson · p = 0.0451
SecondaryCorrelation of Gene Expression in Tumor and Adjacent Mucosa

Concentration of the gene expression was analysed in both tumor and adjacent mucosa. The presence of any correlation between the results (i.e., concentration of the gene expression in tumor versus adjacent mucosa) was evaluated for each treatment. No evaluation was done between treatments.

Time frame:
Sample taken Day 1 (Day of Surgery)
Reported as:
Number · Normalized concentration
Correlation of Gene Expression in Tumor and Adjacent Mucosa
Normalized concentrationLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
AMT-0.47193-0.707300.754040.42972
PCFT0.114970.899760.585020.88128
FPGS0.17664-0.647430.886820.97624
MTHFS0.958400.584190.431940.94364
ABCC30.003220.77700-0.25891-0.38987
GGH0.78928-0.097370.468830.93711
ABCC10.747570.14436-0.167240.82963
MTHFD1L0.744590.209550.371600.32113
SHMT10.591830.055310.678530.50966
SHMT20.55508-0.716660.862660.81040
RFC-10.64565-0.024500.233120.31800
Statistical analysis
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.3359 · Correlation factor: 0.42972
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.0307 · Correlation factor: 0.75404
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.1160 · Correlation factor: -0.70730
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.2377 · Correlation factor: -0.47193
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.0087 · Correlation factor: 0.88128
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.1277 · Correlation factor: 0.58502
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.0146 · Correlation factor: 0.89976
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.7863 · Correlation factor: 0.11497
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.0002 · Correlation factor: 0.97624
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.0033 · Correlation factor: 0.88682
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.1645 · Correlation factor: -0.64743
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.6756 · Correlation factor: 0.17664
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.0014 · Correlation factor: 0.94364
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.2852 · Correlation factor: 0.43194
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.2234 · Correlation factor: 0.58419
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.0002 · Correlation factor: 0.95840
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.3873 · Correlation factor: -0.38987
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.5358 · Correlation factor: -0.25891
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.0691 · Correlation factor: 0.77700
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.9940 · Correlation factor: 0.00322
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.0018 · Correlation factor: 0.93711
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.2413 · Correlation factor: 0.46883
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.8544 · Correlation factor: -0.09737
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.0199 · Correlation factor: 0.78928
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.0209 · Correlation factor: 0.82963
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.6922 · Correlation factor: -0.16724
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.7850 · Correlation factor: 0.14436
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.0330 · Correlation factor: 0.74757
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.4825 · Correlation factor: 0.32113
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.3647 · Correlation factor: 0.37160
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.6903 · Correlation factor: 0.20955
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.0341 · Correlation factor: 0.74459
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.2426 · Correlation factor: 0.50966
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.0643 · Correlation factor: 0.67853
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.9171 · Correlation factor: 0.05531
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.1222 · Correlation factor: 0.59183
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.0271 · Correlation factor: 0.81040
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.0058 · Correlation factor: 0.86266
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.1090 · Correlation factor: -0.71666
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.1533 · Correlation factor: 0.55508
  • Modufolin 60 mg/m2 · Pearson Correlation · p = 0.4870 · Correlation factor: 0.31800
  • Modufolin 200 mg/m2 · Pearson Correlation · p = 0.5785 · Correlation factor: 0.23312
  • Levoleucovorin 60 mg/m2 · Pearson Correlation · p = 0.9632 · Correlation factor: -0.02450
  • Levoleucovorin 200 mg/m2 · Pearson Correlation · p = 0.0838 · Correlation factor: 0.64565
SecondaryHomocystein Concentration

Blood samples for folate biomarker (homocystein) analysis were collected at Screening, Day 2, and Day 5 (End of study visit).

Time frame:
Samples taken at Screening visit, Day 2, and End of Study (Day 5)
Reported as:
Mean · μmol/L
Homocystein Concentration
μmol/LLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
Concentration at Screening12.59 ± 4.2811.27 ± 3.9814.53 ± 6.2213.80 ± 3.83
Concentration at Day 26.41 ± 2.326.40 ± 3.107.06 ± 1.978.14 ± 2.63
Concentration at Day 59.04 ± 2.539.18 ± 4.6510.20 ± 3.3410.10 ± 2.64
SecondaryS-Folate Concentration

Blood samples for folate biomarker (S-folate) analysis were collected at Screening, Day 2 and Day 5 (End of study visit).

Time frame:
Samples taken at Screening visit, Day 2 and End of Study (Day 5)
Reported as:
Mean · nmol/L
S-Folate Concentration
nmol/LLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2
Concentration at Screening21.75 ± 8.8821.00 ± 6.5415.03 ± 5.2018.71 ± 7.65
Concentration at Day 245.00 ± 0.0045.00 ± 0.0045.00 ± 0.0045.00 ± 0.00
Concentration at Day 544.75 ± 0.7140.80 ± 9.3944.14 ± 2.2740.29 ± 3.73
SecondaryChange in Homocystein Concentration From Screening

Blood samples for folate biomarker (homocystein) analysis were collected at Screening, Day 2 and Day 5 (End of study visit). Changes from screening to later visits were counted. The criteria for assessment categories "normal", "low" and "high" were based on the reference ranges for plasma-Homocystein as follows: "low" \<4,7 mcmol/L; "normal" =\> 4,7 and \<=16 mcmol/L; "high" \>16 mcmol/L. Values were applicable for both male and female adults.

Time frame:
Samples taken at Screening visit, Day 2 and End of Study (Day 5)
Reported as:
Count of participants · Participants
Change in Homocystein Concentration From Screening
ParticipantsModufolin 60 mg/m2Modufolin 200 mg/m2Levoleucovorin 60 mg/m2Levoleucovorin 200 mg/m2
Normal at Screen and Normal at Day 25444
Shift from Normal at Screen to Low at Day 20122
Shift from High at Screen to Normal at Day 22302
Normal at Screen and Normal at Day 55546
Shift from Normal at Screen to Low at Day 50010
Shift from High at Screen and Normal at Day 52302
Missing data Screen to Day 50010
SecondaryChange in S-Folate Concentration From Screening

Blood samples for folate biomarker (S-folate) analysis were collected at Screening, Day 2 and Day 5 (End of study visit). Changes from screening to later visits were counted.

Time frame:
Samples taken at Screening visit, Day 2 and End of Study (Day 5)
Reported as:
Count of participants · Participants
Change in S-Folate Concentration From Screening
ParticipantsModufolin 60 mg/m2Modufolin 200 mg/m2Levoleucovorin 60 mg/m2Levoleucovorin 200 mg/m2
Shift from Normal at Screen to High at Day 27858
Missing data Screen to Day 20010
Normal at Screening and Normal at Day 53110
Shift from Normal at Screen to High at Day 54648
Missing data Screen to Day 50110
SecondaryNumber of AEs Per Severity

Number of reported AEs per treatment with respect to severity

Time frame:
Screening visit until end of study, Day 5
Reported as:
Number · Events
Number of AEs Per Severity
EventsLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin mg/m2
AEs of mild severity1015
AEs of moderate severity3072
AEs of severe severity0122

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levoleucovorin 200 mg/m2—0/8 (0%)4/8 (50%)
Levoleucovorin 60 mg/m2—1/7 (14.3%)2/7 (28.6%)
6R-MTHF 200 mg/m2—2/8 (25%)4/8 (50%)
6R-MTHF 60 mg/m2—2/8 (25%)5/8 (62.5%)
Most frequent serious events
Most frequent serious events
EventLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m26R-MTHF 200 mg/m26R-MTHF 60 mg/m2
Cardiac arrestCardiac disorders0/81/70/80/8
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/80/70/81/8
Acute mycardial infarctionCardiac disorders0/80/70/81/8
Postoperative wound complicationInjury, poisoning and procedural complications0/80/71/80/8
Anastomotic leakInjury, poisoning and procedural complications0/80/71/80/8
Most frequent other events
Showing 10 of 15
Most frequent other events
EventLevoleucovorin 200 mg/m2Levoleucovorin 60 mg/m26R-MTHF 200 mg/m26R-MTHF 60 mg/m2
DyspepsiaGastrointestinal disorders0/80/70/82/8
Atrial fibrillationCardiac disorders2/80/72/80/8
ParalysisNervous system disorders0/81/70/80/8
DysphoniaRespiratory, thoracic and mediastinal disorders0/81/70/80/8
PneumoniaInfections and infestations0/80/71/81/8
CoughRespiratory, thoracic and mediastinal disorders0/80/70/81/8
FlushingVascular disorders0/80/70/81/8
HypotensionVascular disorders0/80/70/81/8
VomitingGastrointestinal disorders0/80/71/81/8
NauseaGastrointestinal disorders0/80/71/80/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Levoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2Total
<=18 years00000
Between 18 and 65 years03227
>=65 years856625
Age, Continuous
Age, Continuous(years)Levoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2Total
Mean80.5 ± 9.1566.71 ± 16.8972 ± 1571.75 ± 11.2572.74 ± 13.07
Sex: Female, Male
Sex: Female, Male(Participants)Levoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2Total
Female453416
Male435416
Region of Enrollment
Region of Enrollment(Participants)Levoleucovorin 200 mg/m2Levoleucovorin 60 mg/m2Modufolin 200 mg/m2Modufolin 60 mg/m2Total
Sweden888832
08

Study locations

1 site
  • Sahlgrenska University Hospital
    Gothenburg, 461 85, Sweden
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2012
First posted
Sep 10, 2012
Start
Sep 2012
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Jul 17, 2015
Last update
Sep 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01681472
Lead sponsor
Isofol Medical AB
Responsible party
Sponsor
First posted
Sep 10, 2012
Start date
Sep 2012
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Jul 17, 2015
Last update
Sep 25, 2020

Study contacts

Kristoffer Derwinger, MD PhD
principal investigator · Sahlgrenska University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: L-(+)-methylenetetrahydrofolic acid

Start the discussion